Discovery of novel drugs for promising targets

Clinical Therapeutics

Volumn 35, Issue 9, 2013, Pages 1271-1281

  Martell, Robert E ^a,b   Brooks, David G ^a   Wang, Yan ^a   Wilcoxen, Keith ^a  

^a TESARO   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cancer; Drug discovery

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; OLAPARIB; PERTUZUMAB; SORAFENIB; TRASTUZUMAB; VEMURAFENIB;

CANCER PATIENT; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG DESIGN; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; INFORMATION SCIENCE; MELANOMA; NONHUMAN; ONCOGENE; REVIEW; TUMOR CELL LINE; VALIDATION PROCESS;

CANCER; DRUG DISCOVERY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84884313181     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.08.005     Document Type: Review

References (84)

1. Musacchio T., Torchilin V.P. siRNA delivery: from basics to therapeutic applications. Front Biosci (Landmark Ed) 2013, 18:58-79.
2. Natrajan R., Wilkerson P. From integrative genomics to therapeutic targets. Cancer Res 2013, 73:3483-3488.
3. Yap T.A., Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012, 52:549-573.
4. Sawyers C.L. Shifting paradigms: the seeds of oncogene addiction. Nat Med 2009, 15:1158-1161.
5. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
6. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
7. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol 2011, 103:464-467.
8. Katayama R., Shaw A.T., Khan T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012, 4:120ra17.
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
10. Swain S.M., Kim S.B., Cortés J., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461-471.
11. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011, 5:387-393.
14. Ashworth A., Lord C.J., Reis-Filho J.S. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
15. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366:1382-1392.
16. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979.
17. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
18. Davis M.I., Hunt J.P., Herrgard S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1046-1051.
19. Jubb H., Higueruelo A.P., Winter A., Blundell T.L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci 2012, 33:241-248.
20. Keskin O., Gursoya A., Ma B., Nussinov R. Towards drugs targeting multiple proteins in a systems biology approach. Curr Top Med Chem 2007, 7:943-951.
21. Jahnke W., Grotzfeld R.M., Pellé V., et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc 2010, 132:7043-7048.
22. Heald R.A., Jackson P., Savy P., et al. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J Med Chem 2012, 55:4594-4604.
23. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
24. Valkov E., Sharpe T., Marsh M., et al. Targeting protein-protein interactions and fragment-based drug discovery. Top Curr Chem 2012, 317(145-179):22.
25. Michnick S.W., Ear P.H., Manderson E.M., et al. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat Rev Drug Discov 2007, 6:569-582.
26. Higueruelo A.P., Schreyer A., Bickerton G.R., et al. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 2009, 74:457-467.
27. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
28. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790.
29. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012, 12(12):801-817.
30. Hertzberg R.P., Pope A.J. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000, 4:445-451.
31. Liu B., Li S., Hu J. Technological advances in high-throughput screening. Am J Pharmacogenomics 2004, 4:263-276.
32. Deng H., O'Keefe H., Davie C.P., et al. Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT). J Med Chem 2012, 55:7061-7079.
33. Kleiner R.E., Dumelin C.E., Liu D.R. Small-molecule discovery from DNA-encoded chemical libraries. Chem Soc Rev 2011, 40:5707-5717.
34. Mannocci L., Leimbacher M., Wichert M., et al. 20 years of DNA-encoded chemical libraries. Chem Commun (Camb) 2011, 47:12747-12753.
35. Hoffer L., Renaud J.P., Horvath D. Fragment-based drug design: computational & experimental state of the art. Comb Chem High Throughput Screen 2011, 14:500-520.
36. Sukumar N., Das S. Current trends in virtual high throughput screening using ligand-based and structure-based methods. Comb Chem High Throughput Screen 2011, 14:872-888.
37. Gajiwala K.S., Feng J., Terre R., et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 2013, 21:209-219.
38. Cai Q., Sun H., Peng Y., et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011, 54:2714-2726.
39. Sun H., Stuckey J.A., Nikolovska-Coleska Z., et al. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 2008, 51:7169-7780.
40. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
41. Sukumar N., Krein M.P., Embrechts M.J. Predictive cheminformatics in drug discovery: statistical modeling for analysis of micro-array and gene expression data. Methods Mol Biol 2012, 910:165-194.
42. Wild D.J., Ding Y., Sheth A.P., et al. Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. Drug Discov Today 2012, 17:469-474.
43. Chen H., Xie G. The use of web ontology languages and other semantic web tools in drug discovery. Expert Opin Drug Discov 2010, 5:413-423.
44. Bredel M., Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004, 5:262-275.
45. Klabunde T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol 2007, 152:5-7.
46. Oloff S., Zhang S., Sukumar N., et al. Chemometric analysis of ligand receptor complementarity: identifying Complementary Ligands Based on Receptor Information (CoLiBRI). J Chem Inf Model 2006, 46:844-851.
47. Vulpetti A., Kalliokoski T., Milletti F. Chemogenomics in drug discovery: computational methods based on the comparison of binding sites. Future Med Chem 2012, 4:1971-1979.
48. Ren J., Xie L., Li W.W., Bourne P.E. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res 2010, 38(Web Server issue):W441-W444.
49. Kinnings S.L., Jackson R.M. LigMatch: a multiple structure-based ligand matching method for 3D virtual screening. J Chem Inf Model 2009, 49:2056-2066.
50. Das S., Krein M.P., Breneman C.M. Binding affinity prediction with property-encoded shape distribution signatures. J Chem Inf Model 2010, 50:298-308.
51. Milletti F., Vulpetti A. Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model 2010, 50:1418-1431.
52. Martin E., Mukherjee P., Sullivan D., Jansen J. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity. J Chem Inf Model 2011, 51:1942-1956.
53. Martin E., Mukherjee P. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. J Chem Inf Model 2012, 52:156-170.
54. Martin E.J., Sullivan D.C. AutoShim: empirically corrected scoring functions for quantitative docking with a crystal structure and IC50 training data. J Chem Inf Model 2008, 48:861-872.
55. Warren G.L., Andrews C.W., Capelli A.M., et al. A critical assessment of docking programs and scoring functions. J Med Chem 2006, 49:5912-5931.
56. Martin E.J., Sullivan D.C. Surrogate AutoShim: predocking into a universal ensemble kinase receptor for three dimensional activity prediction, very quickly, without a crystal structure. J Chem Inf Model 2008, 48:873-881.
57. Schroder J., Killinger A., Oellien F., et al. Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. J Med Chem 2013, 56:1478-1490.
58. Mulrooney C.A., Lahr D.L., Quintin M.J., et al. An informatic pipeline for managing high- throughput screening experiments and analyzing data from stereo- chemically diverse libraries. J Comput Aided Mol Des 2013, 27:445-468.
59. Browning M.R., Calhoun B.T., Swamidass S.J. Managing missing measurements in small-molecule screens. J Comput Aided Mol Des 2013, 27:469-478.
60. Rowbottom M.W., Faraoni R., Chao Q., et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropa n-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem 2012, 55:1082-1105.
61. Gillet J.P., Varma S., Gottesman M.M. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013, 105:452-458.
62. Barretina J., Caponigro G., Stransky N., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
63. Wang Y., Revelo M., Sudilovsky D., et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64:149-159.
64. McDermott U., Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009, 27:5650-5659.
65. McDermott U., Sharma S.V., Settleman J. High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol 2008, 438:331-341.
66. McDermott U., Sharma S.V., Dowell L., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007, 104:19936-19941.
67. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
68. Garnett M.J., Edelman E.J., Heidorn S.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
69. Gurski L.A., Petrilli N.J., Jia X., Farach-Carson M.C. 3D Matrices for Anti-Cancer Drug Tesing and Development. Oncology Issues 2010, 20-25.
70. LaBarbera D.V., Reid B.G., Yoo B.H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov 2012, 7:819-830.
71. Nyga A., Cheema U., Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 2011, 5:239-248.
72. Carver B.S., Pandolfi P.P. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006, 12:5305-5311.
73. Cespedes M.V., Isolda C., Matilde P., Ramón M. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006, 8:318-329.
74. Teicher B.A. Tumor models for efficacy determination. Mol Cancer Ther 2006, 5:2435-2443.
75. Wendler A., Wehling M. The translatability of animal models for clinical development: biomarkers and disease models. Curr Opin Pharmacol 2010, 10:601-606.
76. Firestone B. The challenge of selecting the 'right' in vivo oncology pharmacology model. Curr Opin Pharmacol 2010, 10:391-396.
77. Tentler J.J., Tan A.C., Weekes C.D., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9:338-350.
78. Dangles-Marie V., Pocard M., Richon S., et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007, 67:398-407.
79. Taetle R., Rosen F., Abramson I., et al. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987, 71:297-304.
80. Wennerberg J., Trope C., Biorklund A. Heterotransplantation of human head and neck tumours into nude mice. Acta Otolaryngol 1983, 95:183-190.
81. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10. 1311-1136.
82. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011, 10:3-8.
83. Notice. Fed Regist 2010, 75:10487-10488. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability.
84. Ponce R. ICH S9: Developing anticancer drugs, one year later. Toxicol Pathol 2011, 39:913-915.